Impact News +++ Quanta Services übertrifft im 3. Quartal 2025 die Erwartungen, Aktie gibt dennoch nach (Investing.com DE) +++ QUANTA SERVICES Aktie +3,43%

OPKO HEALTH Aktie

>OPKO HEALTH Aktienkurs

1.2485 EUR (Tradegate)

Ask: 1.259 EUR / 8000 Stück

Bid: 1.238 EUR / 8100 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

OPKO HEALTH Aktie über LYNX handeln

Intraday

1 Jahr

>OPKO HEALTH Performance

1 Woche: -2,8%

1 Monat: +1,4%

3 Monate: +8,1%

6 Monate: +4,2%

1 Jahr: -13,3%

laufendes Jahr: -10,5%

>OPKO HEALTH Aktie

Name:

OPKO HEALTH INC. DL-,01

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US68375N1037 / A0MUUJ

Symbol/ Ticker:

XCY (Frankfurt) / OPK (NASDAQ)

Kürzel:

FRA:XCY, ETR:XCY, XCY:GR, NASDAQ:OPK

Index:

Webseite:

https://www.opko.com/

Profil:

Opko Health Inc. is a diversified healthcare compa..
>Volltext..

Marktkapitalisierung:

987.94 Mio. EUR

Unternehmenswert:

1093.18 Mio. EUR

Umsatz:

569.93 Mio. EUR

EBITDA:

-148.33 Mio. EUR

Nettogewinn:

-152.07 Mio. EUR

Gewinn je Aktie:

-0.2 EUR

Schulden:

339.68 Mio. EUR

Liquide Mittel:

233.23 Mio. EUR

Operativer Cashflow:

-205.54 Mio. EUR

Bargeldquote:

1.59

Umsatzwachstum:

-15.72%

Gewinnwachstum:

33.74%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

OPKO HEALTH

Letzte Datenerhebung:

30.10.25

>OPKO HEALTH Kennzahlen

Aktien/ Unternehmen:

Aktien: 793.78 Mio. St.

Frei handelbar: 44.83%

Leerverk. Aktien: 4.2%

Rückkaufquote: 5.09%

Mitarbeiter: 2997

Umsatz/Mitarb.: 0.2 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 155.45%

Bewertung:

KGV: -

KGV lG: -

KUV: 1.72

KBV: 0.86

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 20.59%

Gewinnmarge: -26.68%

Operative Marge: -40.29%

Managementeffizenz:

Gesamtkaprendite: -8.96%

Eigenkaprendite: -13.16%

>OPKO HEALTH Peer Group

Es sind 596 Aktien bekannt.

>OPKO HEALTH Chart & Kurs - NASDAQ

>OPKO HEALTH News

30.10.25 - 00:45	Compared to Estimates, OPKO Health (OPK) Q3 Earnings: A Look at Key Metrics (Zacks)
	While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values....

30.10.25 - 00:00	OPKO Health (OPK) Q3 Earnings Surpass Estimates (Zacks)
	OPKO Health (OPK) delivered earnings and revenue surprises of +250.00% and -3.44%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?...

29.10.25 - 21:06	OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results (GlobeNewswire EN)
	Conference call begins at 4:30 p.m. Eastern time today Conference call begins at 4:30 p.m. Eastern time today...

29.10.25 - 14:36	Regeneron Partners With ModeX Therapeutics To Discover And Develop Multispecific Antibodies (AFX)
	WASHINGTON (dpa-AFX) - Wednesday, Regeneron Pharmaceuticals, Inc. (REGN) and ModeX Therapeutics Inc., an OPKO Health company (OPK) entered into a license and collaboration agreement to discover an......

28.10.25 - 22:42	OPKO Health Q3 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

23.10.25 - 21:15	Here′s Why You Should Add OPKO Health Stock to Your Portfolio (Zacks)
	OPK benefits from RAYALDEE momentum, strategic deals and advancing trials amid stiff competition and dependence risks....

22.10.25 - 22:09

OPKO Health to Report Third Quarter 2025 Financial Results on October 29 (GlobeNewswire EN)

MIAMI, Oct. 22, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and nine months ended September 30, 2025 after the close of the U.S. financial markets on Wednesday, October 29, 2025. OPKO's senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on October 29th beginning at 4:30 p.m. Eastern time....

16.09.25 - 03:48	Labcorp Completes $225 Mln Acquisition Of BioReference Health′s Oncology Testing Business (AFX)
	WASHINGTON (dpa-AFX) - Labcorp (LH) and OPKO Health, Inc. announced the completion of Labcorp's acquisition of select BioReference Health assets focused on oncology and oncology-related clinical t......

15.09.25 - 14:33	Labcorp Completes Acquisition of Select Assets of BioReference Health′s Innovative Oncology and Related Clinical Testing Services Businesses (PR Newswire)
	BURLINGTON, N.C. and MIAMI, Sept. 15, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical and diagnostics company, announced today the completion of Labcorp's......

11.09.25 - 19:45	Here′s Why You Should Retain OPKO Health Stock in Your Portfolio (Zacks)
	OPK benefits from RAYALDEE momentum, strategic deals and advancing trials amid stiff competition and dependence risks....

09.08.25 - 03:01	Insiderhandel: CEO & Chairman kauft Aktien von Opko Health im Wert von 891000 USD (Insiderkauf)
	Frost, Phillip Md Et Al - Vorstand - Tag der Transaktion: 2025-08-08...

07.08.25 - 15:00	OPKO Health (OPK) Q2 2025 Earnings Call Transcript (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

01.08.25 - 23:25	Opko Health (OPK) Q2 Revenue Falls 14% (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

01.08.25 - 19:45	OPK Stock Slips Following Q2 Earnings Miss, Gross Margin Expands (Zacks)
	OPKO Health reports wider-than-expected second-quarter 2025 loss and revenue decline, but gross margin expands and product sales remain stable....

01.08.25 - 03:24	OPKO Health outlines $640M–$660M 2025 revenue target as BioReference sale and pipeline advances drive profitability push (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

01.08.25 - 02:30	Compared to Estimates, OPKO Health (OPK) Q2 Earnings: A Look at Key Metrics (Zacks)
	While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values....

01.08.25 - 01:00	OPKO Health (OPK) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
	OPKO Health (OPK) delivered earnings and revenue surprises of -58.33% and -5.09%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?...

31.07.25 - 22:24	OPKO Health GAAP EPS of -$0.19 misses by $0.08, revenue of $156.8M misses by $8.9M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

25.06.25 - 17:03

OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium (GlobeNewswire EN)

MIAMI, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) today announced its participation in the 3rd Annual Piper Sandler Obesity Symposium being held virtually on June 26, 2025. Management will be participating in a fireside discussion moderated by Edward Tentoff, Managing Director, Senior Biotechnology Analyst. Investors can register for the symposium by contacting their Piper Sandler representative....

25.06.25 - 14:03

OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting (GlobeNewswire EN)

MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced that new pharmacologic and pharmacokinetic in vivo data for investigational oral OPK-88006 tablet treatment has been selected for presentation at the ENDO 2025 annual meeting of the Endocrine Society, taking place July 12-15, 2025 in San Francisco, CA, USA....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Der Gelobte glaubt an die Kompetenz der Jury. - Dr. Fritz P. Rinnhofer

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram